Devil Facial Tumours: Towards a Vaccine

References

• Ahmad S, Ranaghan KE, Azam SS. (2019) .Combating tigecycline resistant Acinetobacter baumannii: a leap forward towards multi-epitope based vaccine discovery. Eur J Pharm Sci, 132, 1–17. doi:10.1016/j.ejps.2019.02.023
   PubMed Web of Science ®Google Scholar
• Bartnik A, Nirmal AJ, Yang SY. (2012) .Peptide vaccine therapy in colorectal cancer. Vaccines, 1, 1–16. doi:10.3390/vaccines1010001
   Google Scholar
• Bassani-Sternberg M. (2018) .Mass spectrometry based immunopeptidomics for the discovery of cancer neoantigens. Methods Mol Biol, 1719, 209–221. doi:10.1007/978-1-4939-7537-2_14
   PubMedGoogle Scholar
• Bautz DJ, Sherpa AT, Threadgill DW. (2017) .Prophylactic vaccination targeting ERBB3 decreases polyp burden in a mouse model of human colorectal cancer. OncoImmunology, 6, e1255395. doi:10.1080/2162402X.2016.1255395
   PubMed Web of Science ®Google Scholar
• Beeton N, McCallum H. (2011) .Models predict that culling is not a feasible strategy to prevent extinction of Tasmanian devils from facial tumour disease. J Appl Ecol, 48, 1315–1323. doi:10.1111/j.1365-2664.2011.02060.x
   Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC, Jr, et al. (2004) .Immunopharmacologic analysis of an autologous hapten-modified human melanoma vaccine. J Clin Oncol, 22, 403–415. doi:10.1200/JCO.2004.06.043
   PubMed Web of Science ®Google Scholar
• Biggs J. (2018). 2017 Annual report: Tasmanian devil (Sarcophilus harrisii) conservation program. Zaa, 1, 1–41.
   Google Scholar
• Brohl AS, Kahen E, Yoder SJ, et al. (2017) .The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep, 7, 14992. doi:10.1038/s41598-017-15183-1
   PubMed Web of Science ®Google Scholar
• Brown GK, Kreiss A, Lyons AB, Woods GM. (2011) .Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS One, 6, e24475. doi:10.1371/journal.pone.0024475
   PubMed Web of Science ®Google Scholar
• Brown GK, Tovar C, Cooray AA, et al. (2016) .Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells. Immunol Cell Biol, 94, 673–679. doi:10.1038/icb.2016.38
   PubMed Web of Science ®Google Scholar
• Burnett FM. (1970). The concept of immunological surveillance. Prog Exp Tumor Res, 13, 1–27.
   PubMed Web of Science ®Google Scholar
• Caldwell A, Coleby R, Tovar C, et al. (2018) .The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer. eLife, 7, e35314. doi:10.7554/eLife.42270
   PubMed Web of Science ®Google Scholar
• Chauhan V, Rungta T, Goyal K, Singh MP. (2019) .Designing a multi-epitope based vaccine to combat Kaposi Sarcoma utilizing immunoinformatics approach. Sci Rep, 9, 2517. doi:10.1038/s41598-019-39299-8
   PubMed Web of Science ®Google Scholar
• Cheng Y, Belov K. (2014) .Characterisation of non-classical MHC class I genes in the Tasmanian devil (Sarcophilus harrisii). Immunogenetics, 66, 727–735. doi:10.1007/s00251-014-0804-3
   PubMed Web of Science ®Google Scholar
• Cheng Y, Makara M, Peel E, et al. (2019) .Tasmanian devils with contagious cancer exhibit a constricted T-cell repertoire diversity. Commun Biol, 2, 99. doi:10.1038/s42003-019-0342-5
   PubMed Web of Science ®Google Scholar
• Cheng Y, Stuart A, Morris K, et al. (2012) .Antigen-presenting genes and genomic copy number variations in the Tasmanian devil MHC. BMC Genomics, 13, 1–14. doi:10.1186/1471-2164-13-1
   PubMed Web of Science ®Google Scholar
• Deakin JE, Bender HS, Pearse AM, et al. (2012) .Genomic restructuring in the Tasmanian devil facial tumour: chromosome painting and gene mapping provide clues to evolution of a transmissible tumour. PLoS Genet, 8, e1002483. doi:10.1371/journal.pgen.1002483
   PubMed Web of Science ®Google Scholar
• Epstein B, Jones M, Hamede R, et al. (2016) .Rapid evolutionary response to a transmissible cancer in Tasmanian devils. Nat Commun, 7, 12684. doi:10.1038/ncomms12684
   PubMed Web of Science ®Google Scholar
• Flies A, Lyons A, Corcoran L, et al. (2016) .PD-L1 is not constitutively expressed on Tasmanian devil Facial Tumor Cells but is strongly upregulated in response to IFN-γ and can be expressed in the tumor microenvironment. Front Immunol, 7, 581. doi:10.3389/fimmu.2016.00581
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, et al. (2012) .Trial watch. OncoImmunology, 1, 699–739. doi:10.4161/onci.20696
   PubMed Web of Science ®Google Scholar
• Grueber CE, Reid-Wainscoat E, Fox S, et al. (2017) .Increasing generations in captivity is associated with increased vulnerability of Tasmanian devils to vehicle strike following release to the wild. Sci Rep, 7, 2161. doi:10.1038/s41598-017-02273-3
   PubMed Web of Science ®Google Scholar
• Hamede R, Hogg CJ, Fox S, et al. (2019). Devils and disease in the landscape: the impact of disease on devils in the wild and on the Tasmanian ecosystem. In: Hogg CJ., et al., ed.. Saving the Tasmanian Devil: Recovery through Science-Based Management. Melbourne, Australia: CSIRO Publishing.
   Google Scholar
• Haririan A, Nogueira J, Kukuruga D, et al. (2009) .Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant, 9, 536–542. doi:10.1111/j.1600-6143.2008.02524.x
   PubMed Web of Science ®Google Scholar
• Harper SJ, Ali J, Wlodek E, et al. (2015) .CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection. Proc Natl Acad Sci USA, 112, 12788–12793. doi:10.1073/pnas.1513533112
   PubMed Web of Science ®Google Scholar
• Hawkins CE, Baars C, Hesterman H, et al. (2006) .Emerging disease and population decline of an island endemic the Tasmanian devil (Sarcophilus harrisi). Biol Cons, 131, 307–324. doi:10.1016/j.biocon.2006.04.010
   Web of Science ®Google Scholar
• Hawkins CE, McCallum H, Mooney N, Jones M, Holdsworth M. (2008). Sarcophilus Harrisii. The IUCN Red List of Threatened Species 2008: e.T40540A10331066. Available at: http://dx.doi.org/10.2305/IUCN.UK.2008.RLTS.T40540A10331066.en
   Google Scholar
• Hogg CJ, Ivy J, Srb C, et al. (2015) .Influence of genetic provenance and birth origin on productivity of the Tasmanian devil insurance population. Conserv Genet, 16, 1465–1473. doi:10.1007/s10592-015-0754-9
   Web of Science ®Google Scholar
• Hogg CJ, Lee AV, Srb C, Hibbard C. (2017) .Metapopulation management of an endangered species with limited genetic diversity in the presence of disease: the Tasmanian devil (Sarcophilus harrisii). Int Zoo Yearb, 51, 137–153. doi:10.1111/izy.12144
   Google Scholar
• Jain S, Baranwal M. (2019). Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules. Med Microbiol Immunol, 208(2), 227–238. doi:10.1007/s00430-019-00584-y
   PubMed Web of Science ®Google Scholar
• Jones ME, Cockburn A, Hamede R, et al. (2008) .Life-history change in disease-ravaged Tasmanian devil populations. Proc Natl Acad Sci USA, 105, 10023. doi:10.1073/pnas.0711236105
   PubMed Web of Science ®Google Scholar
• Jones ME, McCallum H (2007). Environmental risk assessment – impact of introduction of Tasmanian devils to Maria island on the natural values of the island. DPIPWE Internal Doc 1B. [online]. Available at: https://www.parks.tas.gov.au/file.aspx?id=26887 [Accessed February 22, 2019].
   Google Scholar
• Keenan BP, Saenger Y, Kafrouni M, et al. (2014) .A listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology, 146, 1784–1794. doi:10.1053/j.gastro.2014.02.055
   PubMed Web of Science ®Google Scholar
• Kimman TG, Vandebriel RJ, Hoebee B. (2007). Genetic variation in response to vaccination. J Community Genet, 10, 201–217.
   Google Scholar
• Kreiss A, Brown G, Tovar C, et al. (2015) .Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations. Vaccine, 33, 3016–3025. doi:10.1016/j.vaccine.2015.01.039
   PubMed Web of Science ®Google Scholar
• Kreiss A, Cheng Y, Kimble F, et al. (2011) .Allorecognition in the Tasmanian devil (Sarcophilus harrisii) an endangered marsupial species with limited genetic diversity. PLoS One, 6, e22402. doi:10.1371/journal.pone.0022402
   PubMed Web of Science ®Google Scholar
• Kreiss A, Fox N, Bergfeld J, et al. (2008) .Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol, 32, 544–553. doi:10.1016/j.dci.2007.09.002
   PubMed Web of Science ®Google Scholar
• Kwon YM, Stammnitz MR, Wang J, et al. (2018) .Tasman-PCR: a genetic diagnostic assay for Tasmanian devil facial tumour diseases. Royal Soc Open Sci, 5, 180870. doi:10.1098/rsos.180870
   PubMed Web of Science ®Google Scholar
• Lachish S, McCallum H, Mann D, et al. (2010) .Evaluation of selective culling of infected individuals to control Tasmanian devil facial tumour disease. Conserv Biol, 24, 841–851. doi:10.1111/j.1523-1739.2009.01429.x
   PubMed Web of Science ®Google Scholar
• Lane A, Cheng Y, Wright B, et al. (2012) .New insights into the role of MHC diversity in Devil Facial Tumour disease. PLoS One, 7, e36955. doi:10.1371/journal.pone.0036955
   PubMed Web of Science ®Google Scholar
• Lazenby B, Tobler M, Brown W, et al. (2018) .Density trends and demographic signals uncover the long-term impact of transmissible cancer in Tasmanian devils. J Appl Ecol, 55, 1368–1379. doi:10.1111/1365-2664.13088
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer E, Maus M, et al. (2013) .Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122, 863–871. doi:10.1182/blood-2013-03-490565
   PubMed Web of Science ®Google Scholar
• Loh R, Bergfeld J, Hayes D, et al. (2006) .The pathology of Devil Facial Tumor Disease (DFTD) in Tasmanian devils (Sarcophilus harrisii). Vet Pathol, 43, 890–895. doi:10.1354/vp.43-6-890
   PubMed Web of Science ®Google Scholar
• Maki J, Guiot A, Aubert M, et al. (2017) .Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review. Vet Res, 48, 57. doi:10.1186/s13567-017-0459-9
   PubMed Web of Science ®Google Scholar
• Marijt KA, Blijleven L, Verdegaal E, et al. (2018) .Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med, 215, 2325. doi:10.1084/jem.20180577
   PubMed Web of Science ®Google Scholar
• Mason D. (1998). A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today, 19, 395–404.
   PubMedGoogle Scholar
• McCallum H, Jones ME, Hawkins C, et al. (2009). Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction. Ecology, 90, 3379–3392.
   PubMed Web of Science ®Google Scholar
• McCallum H, Tompkins D, Jones ME, et al. (2007) .Distribution and impacts of Tasmanian Devil Facial Tumor Disease. EcoHealth, 4, 318–325. doi:10.1007/s10393-007-0118-0
   Web of Science ®Google Scholar
• McCarthy EF. (2006). The toxins of William B Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J, 26, 154–158.
   PubMedGoogle Scholar
• McLennan EA, Gooley R, Wise P, et al. (2018) .Pedigree reconstruction using molecular data reveals an early warning sign of gene diversity loss in an island population of Tasmanian devils (Sarcophilus harrisii). Conserv Genet, 19, 439–450. doi:10.1007/s10592-017-1017-8
   Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, et al. (2013) .Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother, 36, 133–151. doi:10.1097/CJI.0b013e3182829903
   PubMed Web of Science ®Google Scholar
• Murchison EP, Schulz-Trieglaff O, Ning Z, et al. (2012) .Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell, 148, 780–791. doi:10.1016/j.cell.2011.11.065
   PubMed Web of Science ®Google Scholar
• Murchison EP, Tovar C, Hsu A, et al. (2010) .The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science, 327, 84–87. doi:10.1126/science.1180616
   PubMed Web of Science ®Google Scholar
• Nielsen M, Connelley T, Ternette N. (2018) .Improved prediction of Bovine Leucocyte Antigens (BoLA) by use of mass-spectrometry determined ligand and in vitro binding data. J Proteome Res, 17, 559–567. doi:10.1021/acs.jproteome.7b00675
   PubMed Web of Science ®Google Scholar
• Nobeyama Y, Nakagawa H. (2016) .Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. J Dermatol Sci, 81, 118–123. doi:10.1016/j.jdermsci.2015.11.004
   PubMed Web of Science ®Google Scholar
• Ouni N, Chaaben A, Kablouti G, et al. (2019) .The impact of HLA-G 3′UTR polymorphisms in breast cancer in a Tunisian population. Immunol Invest, 48, 1–12. doi:10.1080/08820139.2018.1538235
   PubMed Web of Science ®Google Scholar
• Patchett A, Latham R, Brettingham-Moore K, et al. (2015) .Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil. Dev Comp Immunol, 53, 123–133. doi:10.1016/j.dci.2015.07.003
   PubMed Web of Science ®Google Scholar
• Patchett AL, Tovar C, Corcoran L, et al. (2017) .The toll-like receptor ligands Hiltonol® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol, 76, 352–360. doi:10.1016/j.dci.2017.07.004
   PubMed Web of Science ®Google Scholar
• Pearse AM, Swift K. (2006) .Allograft theory: transmission of devil facial-tumour disease. Nature, 439, 549. doi:10.1038/nature04340
   PubMed Web of Science ®Google Scholar
• Pearse AM, Swift K, Hodson P, et al. (2012) .Evolution in a transmissible cancer: a study of the chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tasmanian devil population. Cancer Genet, 205, 101–112. doi:10.1016/j.cancergen.2011.12.001
   PubMed Web of Science ®Google Scholar
• Pedersen LE, Harndahl M, Rasmussen M, et al. (2011) .Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities. Immunogenetics, 63, 821–834. doi:10.1007/s00251-011-0555-3
   PubMed Web of Science ®Google Scholar
• Pinfold TL, Brown GK, Bettiol SS, Woods GM. (2014) .Mouse model of Devil Facial Tumour Disease established that an effective immune response can be generated against the cancer cells. Front Immunol, 5, 251. doi:10.3389/fimmu.2014.00251
   PubMed Web of Science ®Google Scholar
• Pye RJ, Hamede R, Siddle HV, et al. (2016b) .Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils. Biol Lett, 12, 20160553. doi:10.1098/rsbl.2016.0553
   PubMed Web of Science ®Google Scholar
• Pye RJ, Patchett A, McLennan E, et al. (2018) .Immunization strategies producing a humoral IgG immune response against Devil Facial Tumour Disease in the majority of Tasmanian devils destined for wild release. Front Immunol, 9, 259. doi:10.3389/fimmu.2018.00259
   PubMed Web of Science ®Google Scholar
• Pye RJ, Pemberton D, Tovar C, et al. (2016a) .A second transmissible cancer in Tasmanian devils. Proc Natl Acad Sci USA, 113, 374–379. doi:10.1073/pnas.1519691113
   PubMed Web of Science ®Google Scholar
• Rokhafrooz S, Ghadiri A, Ghandil P, et al. (2018) .Association between HLA-G 14bp gene polymorphism and serum sHLA-G protein concentrations in preeclamptic patients and normal pregnant women. Immunol Invest, 47, 558–568. doi:10.1080/08820139.2018.1467925
   PubMed Web of Science ®Google Scholar
• Ruiz-Aravena M, Jones ME, Carver S, et al. (2018) .Sex bias in ability to cope with cancer: Tasmanian devils and facial tumour disease. Proc Royal Soc B, 285, 20182239. doi:10.1098/rspb.2018.2239
   Web of Science ®Google Scholar
• Save the Tasmanian Devil Programme. (2011). Final report on the Forestier Peninsula Disease Suppression Program. [online]. Available at: https://dpipwe.tas.gov.au/Documents/STDP%20Report%20on%20Disease%20Suppression.pdf. [Accessed April 30, 2019].
   Google Scholar
• Sebille F, Gagne K, Guillet M, et al. (2001) .Direct recognition of foreign MHC determinants by naïve T cells mobilizes specific Vβ families without skewing of the complementarity-determining region 3 length distribution. J Immunol, 167, 3082–3088. doi:10.4049/jimmunol.167.6.3082
   PubMed Web of Science ®Google Scholar
• Siddle HV, Kreiss A, Eldridge M, et al. (2007b) .Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA, 104, 16221–16226. doi:10.1073/pnas.0704580104
   PubMed Web of Science ®Google Scholar
• Siddle HV, Kreiss A, Tovar C, et al. (2013) .Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci USA, 110, 5103–5108. doi:10.1073/pnas.1219920110
   PubMed Web of Science ®Google Scholar
• Siddle HV, Marzec J, Cheng Y, et al. (2010) .MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer. Proc Royal Soc B, 277, 2001–2006. doi:10.1098/rspb.2009.2362
   Web of Science ®Google Scholar
• Siddle HV, Sanderson C, Belov K. (2007a) .Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisi). Immunogenetics, 59, 753–760. doi:10.1007/s00251-007-0238-2
   PubMed Web of Science ®Google Scholar
• Silva A, Mount A, Krstevska K, et al. (2015) .The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J Immunol, 194, 2199–2207. doi:10.4049/jimmunol.1402228
   PubMed Web of Science ®Google Scholar
• Small EJ, Sacks N, Nemunaitis J, et al. (2007) .Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res, 13, 3883–3891. doi:10.1158/1078-0432.CCR-06-2937
   PubMed Web of Science ®Google Scholar
• Stammnitz MR, Coorens T, Gori K, et al. (2018) .The origins and vulnerabilities of two transmissible cancers in Tasmanian devils. Cancer Cell, 33, 607–619. doi:10.1016/j.ccell.2018.03.013
   PubMed Web of Science ®Google Scholar
• Thaunat O, Field A, Dai J, et al. (2005) .Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA, 102, 14723–14728. doi:10.1073/pnas.0507223102
   PubMed Web of Science ®Google Scholar
• Töpfer K, Kempe S, Müller N, et al. (2011) .Tumor evasion from T cell surveillance. J Biomed Biotechnol, 2011, 918471. doi:10.1155/2011/918471
   PubMedGoogle Scholar
• Tovar C, Obendorf D, Murchison EP, et al. (2011) .Tumor-specific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohistochemistry studies. Vet Pathol, 48, 1195–1203. doi:10.1177/0300985811400447
   PubMed Web of Science ®Google Scholar
• Tovar C, Patchett A, Kim V, et al. (2018) .Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease. PLoS One, 13, e0196469. doi:10.1371/journal.pone.0196469
   PubMed Web of Science ®Google Scholar
• Tovar C, Pye RJ, Kreiss A, et al. (2017) .Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Sci Rep, 7, 43827. doi:10.1038/srep43827
   PubMed Web of Science ®Google Scholar
• Vella LA, Yu M, Fuhrmann S, et al. (2009) .Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci USA, 106, 14010–14015. doi:10.1073/pnas.0903225106
   PubMed Web of Science ®Google Scholar
• Vitale I, Sistigu A, Manic G, et al. (2019). Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends Cell Biol, S0962–S8924, 30004–2.
   Google Scholar
• Wei XX, Fong L, Small EJ. (2015) .Prostate cancer immunotherapy with Sipuleucel-T: current standards and future directions. Expert Rev Vaccines, 14, 1529–1541. doi:10.1586/14760584.2015.1099437
   PubMed Web of Science ®Google Scholar
• Wells K, Hamede R, Jones M, et al. (2019) .Individual and temporal variation in pathogen load predicts long-term impacts of an emerging infectious disease. Ecology, 100, e02613. doi:10.1002/ecy.2613
   PubMed Web of Science ®Google Scholar
• Wilson DB, Wilson D, Schroder K, et al. (2004) .Specificity and degeneracy of T cells. Mol Immunol, 40, 1047–1055. doi:10.1016/j.molimm.2003.11.022
   PubMed Web of Science ®Google Scholar
• Wood CG, Mulders P. (2009) .Vitespen: a preclinical and clinical review. Future Oncol, 5, 763–774. doi:10.2217/fon.09.46
   PubMed Web of Science ®Google Scholar
• Woods GM, Kreiss A, Belov K, et al. (2007) .The immune response of the Tasmanian devil (Sarcophilus harrisi) and Devil Facial Tumour Disease. EcoHealth, 4, 338–345. doi:10.1007/s10393-007-0117-1
   Web of Science ®Google Scholar
• Wynne JW, Woon A, Dudek N, et al. (2016) .Characterization of the antigen processing machinery and endogenous peptide presentation of a bat MHC class I molecule. J Immunol, 196, 4468–4476. doi:10.4049/jimmunol.1502062
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung Q, et al. (2014) .Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature, 515, 572–576. doi:10.1038/nature14001
   PubMed Web of Science ®Google Scholar
• Zilberberg J, Feinman R, Korngold R. (2015) .Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Biol Blood Marrow Transplant, 21, 1000–1007. doi:10.1016/j.bbmt.2014.11.001
   PubMed Web of Science ®Google Scholar